![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ROR1 |
Gene summary for ROR1 |
![]() |
Gene information | Species | Human | Gene symbol | ROR1 | Gene ID | 4919 |
Gene name | receptor tyrosine kinase like orphan receptor 1 | |
Gene Alias | NTRKR1 | |
Cytomap | 1p31.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q01973 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4919 | ROR1 | EEC-subject1 | Human | Endometrium | EEC | 1.02e-15 | 5.56e-01 | -0.2682 |
4919 | ROR1 | EEC-subject5 | Human | Endometrium | EEC | 2.41e-02 | 2.24e-01 | -0.249 |
4919 | ROR1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.62e-02 | 2.81e-02 | -0.1883 |
4919 | ROR1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.09e-02 | 1.48e-01 | -0.1934 |
4919 | ROR1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.73e-02 | -3.57e-02 | -0.1916 |
4919 | ROR1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 8.22e-13 | 7.87e-01 | -0.2116 |
4919 | ROR1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 3.57e-02 | 5.86e-01 | -0.1941 |
4919 | ROR1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 6.75e-10 | 6.70e-01 | -0.2119 |
4919 | ROR1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 5.97e-05 | 3.18e-01 | -0.0166 |
4919 | ROR1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.10e-11 | 4.62e-01 | -0.0132 |
4919 | ROR1 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.58e-11 | 3.86e-01 | -0.013 |
4919 | ROR1 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.66e-07 | 4.57e-01 | -0.0121 |
4919 | ROR1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.65e-02 | 5.31e-01 | -0.0961 |
4919 | ROR1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.91e-02 | 5.35e-01 | -0.0876 |
4919 | ROR1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 8.79e-03 | 4.77e-01 | -0.0822 |
4919 | ROR1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 3.91e-04 | 5.95e-01 | -0.0809 |
4919 | ROR1 | HTA12-23-1 | Human | Pancreas | PDAC | 4.22e-05 | 7.91e-01 | 0.3405 |
4919 | ROR1 | HTA12-25-1 | Human | Pancreas | PDAC | 2.61e-04 | 4.90e-01 | 0.313 |
4919 | ROR1 | HTA12-26-1 | Human | Pancreas | PDAC | 2.99e-17 | 8.83e-01 | 0.3728 |
4919 | ROR1 | HTA12-29-1 | Human | Pancreas | PDAC | 2.72e-44 | 9.86e-01 | 0.3722 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001821211 | Thyroid | ATC | peptidyl-tyrosine modification | 156/6293 | 378/18723 | 1.01e-03 | 5.36e-03 | 156 |
GO:004206323 | Thyroid | ATC | gliogenesis | 127/6293 | 301/18723 | 1.07e-03 | 5.66e-03 | 127 |
GO:005109122 | Thyroid | ATC | positive regulation of DNA-binding transcription factor activity | 111/6293 | 260/18723 | 1.32e-03 | 6.88e-03 | 111 |
GO:00181086 | Thyroid | ATC | peptidyl-tyrosine phosphorylation | 153/6293 | 375/18723 | 1.96e-03 | 9.48e-03 | 153 |
GO:000173814 | Thyroid | ATC | morphogenesis of a polarized epithelium | 45/6293 | 94/18723 | 2.86e-03 | 1.30e-02 | 45 |
GO:00600716 | Thyroid | ATC | Wnt signaling pathway, planar cell polarity pathway | 27/6293 | 52/18723 | 4.85e-03 | 1.99e-02 | 27 |
GO:00017363 | Thyroid | ATC | establishment of planar polarity | 34/6293 | 72/18723 | 1.13e-02 | 4.05e-02 | 34 |
GO:00071643 | Thyroid | ATC | establishment of tissue polarity | 34/6293 | 72/18723 | 1.13e-02 | 4.05e-02 | 34 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0431022 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa0431032 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa043108 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
hsa0431011 | Lung | IAC | Wnt signaling pathway | 40/1053 | 171/8465 | 4.56e-05 | 7.06e-04 | 4.69e-04 | 40 |
hsa0431021 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
hsa0431031 | Lung | AIS | Wnt signaling pathway | 39/961 | 171/8465 | 1.29e-05 | 3.32e-04 | 2.12e-04 | 39 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROR1 | SNV | Missense_Mutation | rs201702143 | c.103N>G | p.Ser35Ala | p.S35A | Q01973 | protein_coding | tolerated_low_confidence(0.82) | benign(0.034) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ROR1 | SNV | Missense_Mutation | novel | c.1924N>C | p.Ser642Pro | p.S642P | Q01973 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ROR1 | SNV | Missense_Mutation | rs201702143 | c.103N>G | p.Ser35Ala | p.S35A | Q01973 | protein_coding | tolerated_low_confidence(0.82) | benign(0.034) | TCGA-A2-A0T4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
ROR1 | SNV | Missense_Mutation | rs201702143 | c.103T>G | p.Ser35Ala | p.S35A | Q01973 | protein_coding | tolerated_low_confidence(0.82) | benign(0.034) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ROR1 | SNV | Missense_Mutation | rs866734548 | c.1969N>T | p.Arg657Cys | p.R657C | Q01973 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROR1 | SNV | Missense_Mutation | c.175N>T | p.Thr59Ser | p.T59S | Q01973 | protein_coding | tolerated(0.65) | benign(0.08) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ROR1 | SNV | Missense_Mutation | c.1579N>C | p.Met527Leu | p.M527L | Q01973 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A0XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ROR1 | SNV | Missense_Mutation | c.748N>C | p.Asp250His | p.D250H | Q01973 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ROR1 | SNV | Missense_Mutation | rs749580497 | c.206N>T | p.Thr69Met | p.T69M | Q01973 | protein_coding | tolerated(0.07) | possibly_damaging(0.881) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ROR1 | SNV | Missense_Mutation | rs139362871 | c.1624N>A | p.Val542Ile | p.V542I | Q01973 | protein_coding | tolerated(0.15) | possibly_damaging(0.544) | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4919 | ROR1 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CELL SURFACE | Cirmtuzumab | CIRMTUZUMAB | ||
4919 | ROR1 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CELL SURFACE | ROR1R-CAR-T Cell | |||
4919 | ROR1 | KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME, CELL SURFACE | ROR1 CAR-specific Autologous T-Lymphocytes |
Page: 1 |